Fetoneonatal alloimmune thrombocytopenia (FNAIT): Our experience

      Abstract

      Objective

      Fetoneonatal alloimmune thrombocytopenia (FNAIT) is a relatively rare clinical syndrome characterized by marked thrombocytopenia shortly after birth. It occurs when fetal platelets are destroyed, after sensitization, by a transplacental passage of maternal antibodies directed against a fetal platelet alloantigen inherited from the father. This article reviews some pathophysiologic and clinical aspects of FNAIT.

      Methods

      We also present our experience with the management of 12 newborns affected with a symptomatic form of this disorder in order to verify what would be the best diagnostic and therapeutic protocols.

      Results

      Antibody identification in maternal serum showed 9 anti-HPA-1a (75% of cases), 2 anti-HPA-1b (17%) and 1 anti-HPA-1a + anti-Gp IV + anti-HLA class I (8%).

      Conclusion

      Sixteen human platelet alloantigen (HPA) systems have been identified, six major (from HPA 1 to 5 and HPA 15) and ten rare or private, each composed of two allelic antigens (named “a” or “b”, according to major or minor frequency in the population). All HPA systems, including private or low frequency, may play a role in determining FNAIT. Unfortunately FNAIT cannot be prevented, in fact no one of maternal parameters is predictive of thrombocytopenia or its magnitude.

      Keywords

      To read this article in full you will need to make a payment

      References

        • Kieffer N.
        • Phillips D.R.
        Platelet membrane glycoproteins: Functions in cellular interactions.
        Ann Rev Cell Biol. 1990; 6: 329-357
        • Santoso S.
        Human platelet alloantigens.
        Transfus Apheresis Sci. 2003; 28: 227-236
        • Newman P.J.
        • Derbes R.S.
        • Aster R.H.
        The human platelet alloantigens, PlA1 and PlA2, are associated with a leucine33/proline33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing.
        J Clin Invest. 1989; 83: 1778-1781
        • Kroll H.
        • Kiefel V.
        • Santoso S.
        Clinical aspects and typing of platelet alloantigens.
        Vox Sang. 1998; 74: 345-354
        • Dreyfus M.
        • Kaplan C.
        • Verdy E.
        • Schlegel N.
        • Durand-Zaleski I.
        • Tchernia G.
        Frequency of immune thrombocytopenia in newborns: a prospective study. Immune thrombocytopenia working group.
        Blood. 1997; 89: 4402-4406
        • Doughty H.A.
        • Murphy M.F.
        • Metcalfe P.
        • Waters A.H.
        Antenatal screening for fetal alloimmune thrombocytopenia: The results of a pilot study.
        Br J Haematol. 1995; 90: 321-325
        • Kaplan C.
        • Morel-Kopp M.C.
        • Forestier F.
        • Dreyfus M.
        • Daffos F.
        • Tchernia G.
        Fetal-neonatal thrombocytopenia of immunologic origin: Current aspects.
        Pathol Biol (Paris). 1994; 42: 783-789
        • de Vries L.S.
        • Connell J.
        • Bydder G.M.
        • Dubowitz L.M.
        • Rodeck C.H.
        • Mibashan R.S.
        • et al.
        Recurrent intracranial haemorrhages in utero in an infant with alloimmune thrombocytopenia. Case report.
        Br J Obstet Gynaecol. 1988; 95: 299-302
        • Muniz-Diaz E.
        • Ginovart Galiana G.
        Fetal-neonatal alloimmune thrombocytopenia.
        An Pediatr (Barc). 2003; 58: 562-567
        • Durand-Zaleski I.
        • Schlegel N.
        • Blum-Boisgard C.
        • Uzan S.
        • Dreyfus M.
        • Kaplan C.
        Screening primiparous women and newborns for fetal/neonatal alloimmune thrombocytopenia: A prospective comparison of effectiveness and costs. Immune thrombocytopenia working group.
        Am J Perinatol. 1996; 13: 423-431
        • Rachel J.M.
        • Summers T.C.
        • Sinor L.T.
        • Plapp F.V.
        Use of a solid phase red blood cell adherence method for pretransfusion platelet compatibility testing.
        Am J Clin Pathol. 1988; 90: 63-68
        • Moore S.B.
        • DeGoey S.R.
        Serum platelet antibody testing: Evaluation of solid-phase enzyme immunoassay and comparison with indirect immunofluorescence.
        Am J Clin Pathol. 1998; 109: 190-195
        • Kiefel V.
        • Santoso S.
        • Weisheit M.
        • Mueller-Eckhardt C.
        Monoclonal antibody-specific immobilization of platelet antigens (MAIPA): A new tool for the identification of platelet-reactive antibodies.
        Blood. 1987; 70: 1722-1726
        • Simsek S.
        • Faber N.M.
        • Bleeker P.M.
        • Vlekke A.B.
        • Huiskes E.
        • Goldschmeding R.
        • et al.
        Determination of human platelet antigen frequencies in the Dutch population by immunophenotyping and DNA (allele-specific restriction enzyme) analysis.
        Blood. 1993; 81: 835-840
        • Unkelbach K.
        • Kalb R.
        • Santoso S.
        • Kroll H.
        • Mueller-Eckhardt C.
        • Kiefel V.
        Genomic RFLP typing of human platelet alloantigens Zw(PlA), Ko, Bak and Br (HPA-1, 2, 3, 5).
        Br J Haematol. 1995; 89: 169-176
        • Davoren A.
        • McParland P.
        • Barnes C.A.
        • Murphy W.G.
        Neonatal alloimmune thrombocytopenia in the Irish population: a discrepancy between observed and expected cases.
        J Clin Pathol. 2002; 55: 289-292
        • Gruel Y.
        • Boizard B.
        • Daffos F.
        • Forestier F.
        • Caen J.
        • Wautier J.L.
        Determination of platelet antigens and glycoproteins in the human fetus.
        Blood. 1986; 68: 488-492
        • Kiefel V.
        • Konig C.
        • Kroll H.
        • Santoso S.
        Platelet alloantibodies in transfused patients.
        Transfusion. 2001; 41: 766-770
        • Murphy M.F.
        • Metcalfe P.
        • Waters A.H.
        • Ord J.
        • Hambley H.
        • Nicolaides K.
        Antenatal management of severe feto-maternal alloimmune thrombocytopenia: HLA incompatibility may affect responses to fetal platelet transfusions.
        Blood. 1993; 81: 2174-2179
        • King K.E.
        • Kao K.J.
        • Bray P.F.
        • Casella J.F.
        • Blakemore K.
        • Callan N.A.
        • et al.
        The role of HLA antibodies in neonatal thrombocytopenia: A prospective study.
        Tissue Antigens. 1996; 47: 206-211
        • L’Abbè D.
        • Tremblay L.
        • Filion M.
        • Busque L.
        • Goldman M.
        • Decary F.
        • et al.
        Alloimmunization to platelet antigen HPA-1a (PIA1) is strongly associated with both HLA-DRB30101 and HLA-DQB10201.
        Hum Immunol. 1992; 34: 107-114
        • Decary F.
        • L’Abbè D.
        • Tremblay L.
        • Chartrand P.
        The immune response to the HPA-1a antigen: Association with HLA-DRw52a.
        Transfus Med. 1991; 1: 55-62
        • Kaplan C.
        Immune thrombocytopenia in the foetus and the newborn: Diagnosis and therapy.
        Transfus Clin Biol. 2001; 8: 311-314
        • Birchall J.E.
        • Murphy M.F.
        • Kaplan C.
        • Kroll H.
        European collaborative study of the antenatal management of feto-maternal alloimmune thrombocytopenia.
        Br J Haematol. 2003; 122: 275-288
        • Glassman A.B.
        • Shieh W.J.
        Neonatal alloimmune thrombocytopenia: Current considerations.
        Ann Clin Lab Sci. 1994; 24: 407-411
        • Kaplan C.
        • Murphy M.F.
        • Kroll H.
        • Waters A.H.
        Feto-maternal alloimmune thrombocytopenia: antenatal therapy with IVIgG and steroids – more questions than answers. European Working Group on FMAIT.
        Br J Haematol. 1998; 100: 62-65
        • Rothenberger S.
        Neonatal alloimmune thrombocytopenia.
        Ther Apher. 2002; 6: 32-35